The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell CarcinomaRana R. McKay, Toni K. Choueiri, Xiao X. Wei et al.|Cancer Immunology Research|2018Cited by 136
Genomic landscape and clinical characteristics of patients (pts) with neuroendocrine prostate cancer (NEPC) with or without aggressive variant prostate cancer characterized by molecular signature (AVPC-MS).Hedyeh Ebrahimi, Alex Chehrazi‐Raffle, Regina Barragán-Carrillo et al.|Journal of Clinical Oncology|2025Cited by 1
Assessment of time from cytoreductive nephrectomy (CN) to initiation of targeted therapy (TT) in patients with metastatic renal cell carcinoma (mRCC).Winston Vuong, Sumanta Kumar Pal, Mark Chang et al.|Journal of Clinical Oncology|2014Cited by 0
Abstract 3911: Use of ALK inhibitors in patients with non-lung malignancies bearing <i>ALK</i> alteration prolongs treatment duration.Vitor Góes, Sumanta Kumar Pal, Miguel Zugman et al.|Cancer Research|2026Cited by 0